Copy
HYPERTHERMIA NEWS - SEPTEMBER 2019 | ONLINE VERSION
Dr. Sennewald

HYPERTHERMIA NEWS

Dear <<Title>> <<Last name>>,

This fall gets underway with the IV International Conference in Memory of Academician A.F. Tsyb,Combination Therapy in Oncology: Novel Trends”. Organized as part of the Second International Forum of Oncology and Radiology (in accordance with the Plan of Scientific Events of the Ministry of Health of the Russian Federation), this will take place at the Medical Radiological Scientific Center in Obninsk on September 27. Important topics covered by the international experts in the field include “Pencil Beam Scanning Proton Therapy and Hyperthermia” and “Hyperthermia as Immune Modulator in Multimodal Tumor Therapies” (see below for the detailed program).

 
Best regards,

Dr. Sennewald Medizintechnik GmbH

CONFERENCE IN OBNINSK, RUSSIA

Combination Therapy in Oncology: Novel Trends
THE SECOND INTERNATIONAL FORUM ON ONCOLOGY AND RADIOLOGY
IV International Conference in Memory of Academician A.F. Tsyb
“Combination Therapy in Oncology: Novel Trends”
Obninsk, Russia | September 27, 2019


CHAIRPERSONS:
Andrey Kaprin MD PhD, Ministry of Health, Russia
Sergey Ivanov MD, A.F. Tsyb Medical Radiological Research Center, Obninsk, Russia
Boris Dolgushin MD PhD, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia
Igor Kvetnoy PhD, Ott Research Institute of Obstetrics, Gynecology and Reproduction, Saint Petersburg, Russia
Rainer Rienmueller MD PhD, Foreign member of the Russian Academy of Sciences, Graz, Austria
Rainer Fietkau MD PhD, University Hospital Erlangen, Germany

 
  • Elizabeth Repasky MD PhD, Roswell Park Cancer Institute, Buffalo, USA, “Understanding How Stress Affects Immune Suppression, Tumor Growth and The Efficacy of Immunotherapy and Radiation Therapy”
  • Roman Ivanov MD PhD, BIOCAD, Saint Petersburg, Russia, “Immunotherapy of Cancer Diseases – Present and Future”
  • Georgios Lymouris MD PhD, National and Kapodistrian University of Athens, Greece, “Current Radio‐Molecular Targeted Therapy as Evolutionary Precision‐Treatment”
  • Igor Kvetnoy PhD, Ott Research Institute of Obstetrics, Gynecology and Reproduction, Saint Petersburg, Russia, “Molecular Microscopy: Role and Significance in Personalized Diagnostics and Target Therapy of Tumors”
  • Lyudmila Grivtsova PhD, A.F. Tsyb Medical Radiological Research Center, Obninsk, Russia, “Stemcells. Our Experience in The Application in Oncologic Patients”
  • Jasna Mihailovic PhD, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia, “Radioiodine Therapy for Thyroid Cancer. Modern European Recommendations and Trends”
  • Fridtjof Nuesslin MD PhD, Klinikum Rechts der Isar, Munich, Germany, “Radio‐Omics – A New Approach of Quantitative Imaging in Radio‐Oncology”
  • Kalevi Kairemo MD PhD , Docrates Cancer Center, Helsinki, Finland, “Prerequisites of a Clinical Theranostics Department – PET/Radionuclide Therapy Applications in Routine Practice”
  • Ido Wolf MD PhD , Tel-Aviv Sourasky Medical Center, Israel, “Implementing Genomic Tests in the Oncology Clinic: Time for a Paradigm Shift”
  • Rainer Fietkau MD PhD, University Hospital Erlangen, Germany, “Combination of Hyperthermia, Chemo‐ and Radiotherapy in Various Tumors”
  • Zeljko Vujaskovic MD PhD, University of Maryland, Baltimore, USA, “Integration of Pencil Beam Scanning Proton Therapy and Hyperthermia: The University of Maryland Clinical Experience”
  • Sultan Abdel-Rahman, University Hospital Munich Grosshadern, Germany, “Phase III Study in Pancreatic Cancer and Treatment Approach of Triple Negative Breast Cancer”
  • Niloy Datta MD PhD, Kantonsspital Aarau, Switzerland, “Management of Locally Recurrent Breast Cancers with Local Hyperthermia and Radiotherapy: A Systematic Review and Meta‐Analysis”
  • Jacoba van der Zee MD, Erasmus Medical Center, Rotterdam, The Netherlands, “Beneficial Effects of Hyperthermia in Cancer Patients”
  • Michael Hader, University Hospital Erlangen, Germany, “Hyperthermia as Immune Modulator in Multimodal Tumor Therapies – Immune Biological Rationale”
  • Rainer Rienmueller MD PhD, University Hospital Graz, Austria, “Rationale and Acceptance of Temperature Controlled Hyperthermia in Advanced Oncologic Therapy”

CLINICAL EVIDENCE

As you are aware, a number of important national and international peer-reviewed studies have impressively proven the effectiveness of hyperthermia in combination with chemotherapy or radiotherapy. In summary, the success of hyperthermia treatment can be described as follows:

  • Improvement and extension of medical tumor control
  • Significantly higher success rates for treatment of chemotherapy and radiotherapy
  • Reduction of the tumor size to enable removal by surgery
  • Destruction of tumor cells, especially in cases of previously treatment-resistant tumors
  • Increased remission rates and improvement in the quality of life
  • Long-term improvement in the course of the illness
  • Reduction of the risk of metastases

 In this connection, we recommend you take a look at our recently relaunched website http://www.sennewald.de/en/clinical/bsd-systems-clinical-trials for the first complete listing of clinical studies over the past three decades on the BSD 500 & BSD 2000 covering the effectiveness of adding local and regional hyperthermia to radiation therapy and/or chemotherapy.
 

UPCOMING EVENTS

http://caro-congress.org/en/
http://oegro2019.at/

CONTACT US

Please contact us for specific information and appointment:

MARTIN WADEPOHL
International Sales
martin.wadepohl@sennewald.de

DIRK LUTTER
Sales Manager
dirk.lutter@sennewald.de

MONICA SENNEWALD
Marketing Director
monica.sennewald@sennewald.de

DR. GERHARD SENNEWALD
CEO
gerhard.sennewald@sennewald.de
Dr. Sennewald Medizintechnik GmbH
Schatzbogen 86
Munich 81829
Germany

Add us to your address book

 
Fon: +49 (0)89 542143-0
Fax: +49 (0)89 542143-30
EFAX: +49 (0)89 95464138
Website:
 sennewald.de

Geschäftsführer: Dr. Dipl.-Ing. Gerhard W. Sennewald
Handelsregister: Amtsgericht München HRB 75654
USt-IdNr.: DE 129331634
WEEE-Reg.-Nr.: DE 22905506

Unsubscribe | Update data

You are receiving this email because we assume that you are interested in general information about hyperthermia in clinical oncology.

Copyright © 2019 Dr. Sennewald Medizintechnik GmbH, all rights reserved.